United Therapeutics
Tracked across 4 events · 26 articles · First seen Jan 25, 2025 · Last active Jul 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: United Therapeutics initiated a Phase 2 clinical trial for its EGCg-based investigational therapy for precancerous cervical lesions, which could significantly advance its product pipeline and market position.
May 19, 2026 · 7 articles
Business
Impact: United Therapeutics acquired Thymmune Therapeutics, Inc. for $140 million in cash, with potential earn-out payments up to $160 million. This acquisition expands United Therapeutics' capabilities in regenerative medicine and organ alternatives, aligning with its mission to address rare diseases and organ supply.
Jul 02, 2026 · 7 articles
Business
Impact: United Therapeutics was one of the presenting companies at the Life Sciences Virtual Investor Forum.
Jun 26, 2026 · 6 articles
3D Systems
development partner
↔
United Therapeutics
United Therapeutics partners with 3D Systems to leverage their advanced bioprint
3D Systems
technology partner
↔
United Therapeutics
3D Systems acts as a critical technology partner to United Therapeutics, supplyi
ERGEN INTELLIGENCE
Track United Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard